NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRINALIN is a combination oral tablet containing azatadine maleate (a first-generation H1-receptor antagonist) and pseudoephedrine sulfate (a sympathomimetic decongestant), approved in 1982. It is indicated for symptomatic relief of allergic rhinitis and related upper respiratory congestion. The product addresses both histamine-mediated allergic symptoms and nasal obstruction through dual mechanism action.
LOE Approaching
This legacy product is in late-stage lifecycle with moderate competitive pressure (30), signaling a small, consolidation-focused team focused on defensive market management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRINALIN offers limited career growth opportunities given its LOE-approaching lifecycle and zero linked job postings. This role is best suited for professionals seeking stabilization or cost-management experience rather than launch or expansion-stage career momentum.
Brand ManagerField Sales Representative
Worked on TRINALIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.